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Abstract
Head and neck cancers are among the most prevalent tumors in the world. Despite advances in
the treatment of head and neck tumors, the survival of patients with these cancers has not
markedly improved over the past several decades because of our inability to control and our poor
understanding of the regional and distant spread of this disease. One of the factors contributing to
our poor understanding may be the lack of reliable animal models of head and neck cancer
metastasis. The earliest xenograft models in which human tumor cells were grown in
immunosuppressed mice involved subcutaneous implantation of human head and neck cancer cell
lines. Subcutaneous xenograft models have been popular because they are easy to establish, easy
to manage, and lend themselves to ready quantitation of the tumor burden. More recently,
orthotopic xenograft models, in which the tumor cells are implanted in the tumor site of origin,
have been used with greater frequency in animal studies of head and neck cancers. Orthotopic
xenograft models are advantageous for their ability to mimic local tumor growth and recapitulate
the pathways of metastasis seen in human head and neck cancers. In addition, recent innovations
in cell labeling techniques and small-animal imaging have enabled investigators to monitor the
metastatic process and quantitate the growth and spread of orthopically implanted tumors. This
review summarizes the progress in the development of murine xenograft models of head and neck
cancers. We then discuss the advantages and disadvantages of each type of xenograft model. We
also discuss the potential for these models to help elucidate the mechanisms of regional and distant
metastasis, which could improve our ability to treat head and neck cancers.
Introduction
Head and neck cancers consistently rank among the six
most frequently diagnosed cancers in the world. Cancers
of the oral cavity and pharynx alone account for 337,931
new cases worldwide and 183,613 deaths annually [1]. In
2008, 35,310 new head and neck cancers were diagnosed
in the United States, representing approximately 2.5% of
all cancers diagnosed [2]. Over 90% of head and neck can-
cers are squamous cell carcinomas of the upper aerodiges-
tive tract, including the oral cavity, pharynx, larynx, and
paranasal sinuses. In addition, epithelial head and neck
tumors can arise in the salivary and thyroid glands.
Despite advances in our understanding and advances in
the prevention and treatment of head and neck cancers,
the survival of patients with head and neck cancers has
not significantly improved over the past several decades.
Frequently, treatment failure takes the form of local and
regional recurrences. Our limited understanding of the
mechanisms of local and regional metastasis of these
tumor types thus accounts for the poor prognosis for
patients with head and neck cancers.
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Although no animal model is perfectly applicable to every
kind of human cancer, it is generally agreed that using pre-
clinical animal xenograft tumor models is useful for mod-
eling the growth and spread of disease and for acquiring
information about the mechanisms of action and thera-
peutic efficacy of new antitumor agents. The literature is
replete with articles documenting cancer biology and pre-
clinical evaluations of anticancer agents in xenograft mod-
els for human cancers.
Animal models are being used with greater frequency to
advance our understanding of the mechanisms of regional
and distant metastatic spread of head and neck cancers.
This review summarizes the progress in the development
of murine xenograft models of head and neck cancers.
These models can help elucidate the mechanisms of
regional and distant metastasis to improve our ability to
treat head and neck cancers.
Subcutaneous xenograft models
In 1955, the National Cancer Institute (NCI) began to use
mouse a models bearing rapidly growing murine leuke-
mia cells that had been injected intraperitoneally for sys-
tematic drug screening. These models were successful in
identifying the effect of therapeutic agents against hema-
tologic malignancies, but they were not as useful for devo-
loping agents to treat solid tumors. Xenograft studies of
solid tumors received a major boost in 1971 with the
observation that the athymic nude mice could be used to
establish and grow human tumors [3]. Athymic mice lack
mature T-cells, which are believed to be involved in tumor
immune surveillance and are critical to "self" recognition
and destruction of grafted non-self tissues. This loss of T-
cell function enables cross-species "xenografted" tissues,
including tumor cells, to be tolerated by the immune sys-
tem of the recipient animal.
Most preclinical studies that have been performed using
xenografts tumor models have used subcutaneous
implantation of tumor cells. Several studies have reported
that subcutaneous xenograft models can predict the clini-
cal activity of cytotoxic agents [4-6]. However, other stud-
ies have provided an opposing view. The National Cancer
Institute, NCI retrospectively reviewed 39 agents that had
been studied preclinically using subcutaneous xenograft
models and in phase II clinical trials in human patients.
This analysis revealed that the in vivo anti-tumor activity in
the preclinical animal models did not closely correlate
with therapeutic response in human cancers of the same
histology, except in non-small-cell lung cancers. [7].
Subcutaneous tumor models are advantageous because of
their ease of tumor establishment, measurement, and
reproducibility [8]. However, ectopic subcutaneous
xenograft models are less useful for studying agents that
modulate the tumor microenvironment, as an ectopic site
does not reproduce the primary tumor site microenviron-
ment as well as an orthotopic site does. This rationale has
been used to explain why many therapeutic compounds
that have shown promising activity in subcutaneous
xenograft models revealed disappointing results when
tested in clinical trials [9]. The difference between the drug
activity in preclinical trials and the activity in clinical trials
might be related to the treatment of advanced and/or met-
astatic disease in the clinic. Conventional subcutaneous
xenograft models do not recapitulate advanced local-
regional or distant metastatic disease [10], as they do not
have organ-specific environments for metastatic tumor
cells nor do they represent the common sites of metasta-
sis. For examples, Sharkey and Fogh [11] reported only a
1.3% incidence of metastasis in the subcutaneous site in a
total of 1,045 nude mice involving 11 different tumor
lines.
Xenografts models of head and neck cancers have been
published since the early 1980s. In 1984, Braakhuis et al.
[12] reported on their xenografts model of head and neck
cancer, which were established from fresh surgical speci-
mens from 130 human head and neck cancers implanted
into the subcutaneous tissues of nude mice. Tumor
growth was observed in 26% of the mice, and the highest
rate of growth was observed in animals with poorly differ-
entiated, metastatic, and hypopharyngeal tumors. In
another study, Baker reported that 16 of the 21 squamous
cell carcinoma cell lines (76%) that were heterotrans-
plated into nude mice developed viable tumor nodules. In
these articles, no evidence of metastasis was demonstrated
[13].
Orthotopic xenograft model
One of the first reports on orthotopic xenograft models,
published by Tan et al. in 1977, established orthotopic
transplantation of murine colon adenocarcinomas into
the colon of syngeneic mice, which led to an increase in
hepatic metastases compared to that seen with ectopic
injection [14]. This study by Tan et al. and other studies
have found that orthotopic xenograft models can repre-
sent a more clinically relevant tumor model with respect
to the tumor's primary site and metastasis [8]. In ortho-
topic xenograft models, host microenvironments are
more closely mimicked by implanting tumor cells into the
original anatomical sites when compared to subcutane-
ous xenograft models. Some studies have noted differ-
ences in biological behavior when tumors are grown
subcutaneously relative to tumors grown orthotopically.
Organ-specific environments are also useful for evaluating
anti-tumor therapeutics, as the sensitivity of xenografted
tumors to drugs and/or radiation may be modulated by
their location, and metastasis may be influenced by the
tumor implant sites. One of the advantages of the ortho-Head & Neck Oncology 2009, 1:32 http://www.headandneckoncology.org/content/1/1/32
Page 3 of 6
(page number not for citation purposes)
topic model is that orthotopic implantation of tumor cells
can result in high rates spontaneous tumor metastasis,
whereas the same cells implanted subcutaneously rarely
metastasize [10]. Another advantage of the orthotopic sys-
tem is that attempts to target the processes involved in
local invasion (e.g., inhibition of proteases or interfering
with angiogenesis) can be carried out in a more clinically
relevant site [15]. Finally, some investigators have
described the differences between preclinical drug activity
in subcutaneous and orthotopic models and reported that
orthotopic models are more appropriate for predicting
clinical response [15,16].
Orthotopic xenograft models have some disadvantages as
well. For example, these models can be more technically
challenging to establish and may cause animal morbidity
and even death. Also, for internal, poorly accessible ortho-
topic sites, it can be difficult to evaluate antitumor efficacy
in a continuous way. However, the use of noninvasive
methods to measure tumor volume, including small-ani-
mal magnetic resonance imaging; positron emission tom-
ography; reporter genes with specific fluorescence
properties, such as the stable green fluorescent protein
[17,18]; and the luciferase gene [19], helped to overcome
these obstacles to accurately measure internally implanted
orthotopic tumors [15,20].
Orthotopic xenograft model of head and neck cancers
Orthotopic xenograft models of head and neck squamous
cell carcinomas (HNSCCs) have been reported since the
late 1980s [21-24]. In one of these studies, Fitch et al. [21]
aspirated cells from subcutaneous xenograft models made
from fresh human tumors in nude mice and then injected
these cells into the tongues of nude mice. The authors
reported an 86% of incidence of these implanted oral
tumors [21]. Dinesman et al. [22] implanted tumor cells
into the floor of the mouth through a submandibular
route in nude mice. They reported that 5% of their mice
had lymph node metastases and 40% had pulmonary
metastases, which supports the hypothesis that orthotopic
xenograft models effectively reproduce the patterns of
tumor metastasis seen in human patients. Simon et al.
have reported another floor-of-mouth invasion xenograft
model [24].
Kawashiri et al. reported on an orthotopic sublingual
model of squamous cell carcinoma of the oral tongue
(SCCOT) that had a high incidence of cervical lymph
node metastases [23,25]. Myers et al. also established
orthotopic models of SCCOT through injection of human
cell lines into the oral tongue of nude mice, which led to
the development of cervical lymph node and pulmonary
metastasis [26]. In that article, the authors found that
serial passage of the lymph nodes by isolating the regional
metastases from the cervical lymph nodes after the devel-
opment of orthotopic tongue tumors resulted in a cell line
that was more metastatic than its parental line. Myers et al.
also showed that the tumorigenicity of oral cancer cells
was greater when the cells were injected into the tongue
rather than under the skin of nude mice. Qui et al.
implanted fresh lymph node metastatic human speci-
mens into the tongues of nude mice to establish their
orthotopic model of tongue [27]. These authors reported
that serial passage of the lymph nodes led to the develop-
ment of cell lines that have more potential to metastasize
to the cervical lymph nodes.
Because the oral tongues of the animals can be
approached relatively easily, it is not very complicated to
establish an orthotopic model of oral cancers. In brief, at
our institution, mice are anesthetized, and the tongue is
exposed by grasping it in the midline with a small-toothed
forceps. Then 1 × 103 to 1 × 106, head and neck squamous
cancer cells are injected into the tongue submucosally
using a 1-ml tuberculin syringe with a 30-gauge hypoder-
mic needle. The orthotopic oral tongue cancers in the
nude mouse resemble human SCCOT histologically (Fig-
ure 1). This techniques is relatively easy to establish and
leads to cervical lymph node metastasis, and therefore,
has many potential applications, such as studying the sys-
temic cellular and molecular mechanisms of tumorigenic-
ity, growth, and metastasis of HNSCC and assessing the
effect of novel therapeutic regimens for SCCOT [28-30].
Only a few studies have been published on orthotopic
models for other head and neck cancers. For example, Kim
et al. [31] reported on an orthotopic model for thyroid
carcinoma using anaplastic thyroid carcinoma cell lines.
The authors showed that the tumorigenicity of thyroid
cancer cells was greater when the cells were injected into
the thyroid gland rather than under the skin of nude mice.
Ahn et al. [32] also established an orthotopic model of
papillary thyroid carcinoma in nude mouse using a tech-
nique similar to the technique used by Kim et al[31].
These thyroid orthotopic mouse models have been used
to determined the effect of novel molecularly targeted
agents for aggressive thyroid cancers [33-36].
In another study, Gelbard et al. reported the establish-
ment of an orthotopic mouse model of sinonasal malig-
nancy with a human epidermoid tumor cell lines injected
into the right maxillary sinus or soft palate in nude mice
[37]. Finally, Younes et al. established an orthotopic
model of salivary cancer in the parotid glands of nude
mice and reported treatment efficacy with an epidermal
growth factor receptor/vascular endothelial growth factor
receptor-targeted agent [38]. This same model was also
reported by Choi et al. [39].Head & Neck Oncology 2009, 1:32 http://www.headandneckoncology.org/content/1/1/32
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Although it is difficult to monitor tumor growth and
metastasis spread in orthotopc models, noninvasive imag-
ing methods have been useful for visualizing primary
tumors and cervical lymph node metastasis in orthotopic
models of head and neck cancers. For example, the green
fluorescent protein has been used to image primary oral
squamous cell carcinoma and metastasis [26,40] and bio-
luminescence with the enzyme, firefly luciferase, has been
used for noninvasive in vivo tumor measurement. For this
bioluminescence system, tumor cells need to be trans-
fected with the luciferase gene, and are then given the sub-
strate luciferein prior to imaging [41].
We have used luciferase-transduced SCCOT cell lines and
orthotopic animal models to visualize SCCOT growth and
metastasis in vivo. SCCOT cells were retrovirally infected
with green fluorescent protein and the firefly luciferease
gene with pBMN-I-lucoferase-GFP, and we analyzed the
primary tumor growth and regional metastasis of this
orthotopic mouse model of SCCOT using the IVIS 200
imaging system (Xenogen Corporation, Berkeley, CA)
[30,42]. In this way, we were able to monitor regional
metastasis and quantify the growth of primary SCCOT
using localized photon emission. To monitor the behav-
ior of cervical lymph node metastasis, the partial glossec-
tomy technique can be useful for decreasing emission
Tongue tumor and cervical lymph node metastasis of SCCOT orthotopic xenografts Figure 1
Tongue tumor and cervical lymph node metastasis of SCCOT orthotopic xenografts. (A) Primary tongue tumor 
after orthotopic sublingual implantation of OSC-19 cells isolated from a patient with a well-differentiated squamous cell carci-
noma. The tongues of nude mice were inoculated with OSC-19 cells, and mice were sacrificed after 35 days. Necropsy was 
then performed and an obvious tumor was seen in the tongue. (B) Regional metastasis from orthotopic sublingual implantation 
of luciferase-transduced OSC-19 LN2-Luc cells. OSC-19 LN2-Luc cells were injected into the tips of the mice's tongues. Thir-
teen days after cell inoculation, the primary tumor was removed surgically. On day 82, increased intensity of photon emission 
from the cervical lymph node metastasis was observed. (C) and (D) Hematoxyilin and eosin slides of the OSC-19 tongue 
tumor and cervical lymph node of OSC-19 revealed squamous cell carcinoma in locations (*).
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from the primary tumor and providing longer animal sur-
vival times, giving metastases more time to develop (Fig-
ure 2). Henson et al. have successfully used the luciferase
gene in in vivo in an orthotopic floor of mouth model to
visualize local-tumor growth and metastasis [43]. While
the technique with luciferease-labeled cancer cells has
only been reported by a few investigators to date, it
appears to be useful for monitoring the response to tar-
geted therapeutic agents [30]. This technique will enable
investigators to better study the treatment of regional
metastasis of HNSCC in vivo.
Conclusion
In this review, we describe subcutaneous and orthotopic
models of head and neck cancer, which can be useful tools
for investigating the tumor biology and treatment of head
and neck cancers. Overall, orthotopic xenograft models
have several advantages over ectopic subcutaneous
xenograft models. In addition, the use of small-animal
imaging systems for detecting tumors and metastases
expands the utility of these models for studies on the
mechanisms of tumor progression and metastasis, as well
as for preclinical models of novel therapeutic regimens.
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